Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis. The biotechnology company said Monday that ...

Welcome, nurturing Cancer! You are celebrated for your deep empathy, intuitive nature, and fierce protectiveness of your loved ones. Cancer signs may seem prickly at first meeting, but once they ...

Get a first look at the future of OLED innovation with this exclusive 2025 demo, presented in breathtaking 12K ULTRA HD and HDR at 120 frames per second. Enhanced by Dolby Vision™, this showcase ...

June 30 (Reuters) - Amgen (AMGN.O), opens new tab said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.